Syngene International Limited is a leading contract research, development, and manufacturing organisation serving global pharmaceutical, biotechnology, and allied industries. The market closely tracks Syngene’s performance due to its integrated end-to-end capabilities and long-term client partnerships. In the middle of this evaluation, Syngene International Limited stands out for its unique CRDMO business model, deep scientific talent base, and global delivery footprint. With services spanning discovery, development, and commercial manufacturing, the company’s fundamentals, innovation focus, and governance standards collectively define how investors view its share price over time.

History of Syngene International Ltd

Syngene International Ltd was established in 1993 as part of the Biocon Group, founded by Ms Kiran Mazumdar-Shaw, with the objective of providing high-quality research and development services to global life sciences companies. Over the years, it evolved into a fully integrated CRDMO with capabilities across the drug development lifecycle. Its separate listing on Indian stock exchanges marked an important milestone in its growth journey. This long and specialised operating history often adds perspective when investors assess movements in the Syngene International share price.

Key Personnel of Syngene International Ltd

The company’s leadership team plays a vital role in maintaining scientific excellence and operational discipline, which is often considered while tracking Syngene Intl as a listed entity. The key personnel include:

KIRAN MAZUMDAR SHAW - Non-Executive Director

SANJAYA SINGH - Independent Director

SURESH NARAYANAN - Independent Director

MANJA BOERMAN - Independent Director

KUSH M PARMAR - Independent Director

SHARMILA ABHAY KARVE - Independent Director

VINITA BALI - Non-Executive Director

NILANJAN ROY - Independent Director

CATHERINE PATRICIA ROSENBERG - Non-Executive Director

PETER JAMES JONATHAN BAINS - Executive Director

Business Segments of Syngene Intl Ltd

Syngene International Limited operates across specialised service lines that together define its integrated CRDMO (Contract Research, Development and Manufacturing Organisation) model. Its major business segments include:

Discovery services for small molecules and biologics

Development services, including pre-clinical and clinical support

Contract manufacturing for small molecules and biologics

Integrated research platforms and translational science services

Subsidiaries of Syngene International Ltd

Syngene International Ltd operates through subsidiaries to support global operations and client engagement across regions. The key subsidiaries include:

Syngene Scientific Solutions Limited

Syngene USA Inc

Syngene Manufacturing Solutions Limited

Syngene International Ltd

SYNGENE Share Price